Key Takeaways Current GLP-1 weight-loss meds need to be taken as injections, but new trial results suggest a GLP-1 in pill form could be
Uncategorized
Is Lineage Stock a Buy? Pennington Partners Opens New $3 Million Position in the Company
Pennington Parnters acquired 74,370 shares of Lineage for net position change estimated at $2.91 million. Lineage now represents 1.38% of the firm’s 13F reportable
FAT Brands warns of potential bankruptcy after $1.26 billion debt acceleration
FAT Brands – parent company of Fazoli’s, Round Table Pizza, and Fatburger — may “seek to reorganize through a bankruptcy proceeding” after receiving notices
The Truth About GLP-1 Drugs Causing Hair Loss
Hairloss concept. Young troubled asian woman checking for thinning hair in mirror at home getty As the GLP-1 revolution sweeps through medicine and pop
Where GLP-1s Weight-Loss Drugs Fall Short for Women
Hi! It’s Madison in Chicago. Weight-loss drugs will be a hot topic at my Thanksgiving table — and apparently, they work better for some
Stress-free investing starts with this AI-powered tool, now $55 for life
TL;DR: Invest without stress thanks to this lifetime subscription to Sterling Stock Picker, now $55.19 (reg. $486) with code STOCKS20 through Dec. 7. Credit:
New Novo drug delivers significant weight-loss benefits in diabetes trial
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be
Orforglipron pill shows great weight-loss results in new trial
Orforglipron pill shows great weight-loss results in new trial New clinical trial results revealed that orforglipron could become the first GLP-1 weight-loss drug accessible
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
Novo Nordisk A/S Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks Amycretin demonstrated statistically significant reductions in HbA1c with
SEC Clears Fuse Energy Token in Win for US Crypto ‘Regulatory Clarity’
In brief The SEC has granted no-action relief stating it will not recommend enforcement if Fuse offers and sells its ENERGY token without registration,